Zobrazeno 1 - 10
of 15
pro vyhledávání: '"35"'
Autor:
David Cox, Linda T. Vahdat, Joyce O'Shaughnessy, Erhan Berrak, Stefan Glück, Kristi McIntyre, James Song, Lee S. Schwartzberg
Publikováno v:
Cancer Research. 75:P5-17
Introduction: Eribulin mesylate is a nontaxane microtubule inhibitor approved to treat MBC in patients (pts) who previously received ≥2 chemotherapeutic regimens for MBC. A phase 2 study of first-line eribulin for HER2-negative (HER2-) MBC showed a
Autor:
Jussi M. Halleen, Esa Alhoniemi, Jukka P. Rissanen, Dana T. Aftab, Mari I. Suominen, Katja M. Fagerlund
Publikováno v:
Cancer Research. 75:786-786
Cabozantinib (cabo) is an inhibitor of tyrosine kinases including MET, VEGFR2, RET, and the TAM family kinases TYRO3, AXL, and MER, and has shown clinical activity in patients with castration-resistant prostate cancer and other solid tumors with bone
Autor:
Alexander Gozman, Sanatan Saraf, Iwona Lugowska, Tudor Ciuleanu, Fan Jin, Miguel Quintela-Fandino, Andrew F. Hill, Henry L. Gomez, Karina Vera, Michele Maio, Seock-Ah Im, Ozgur Ozyilkan, Razvan Cristescu, Serhii Lysenko, Michael Schenker, Timothy A. Yap, Ronnie Shapira-Frommer, Anna Kryzhanivska, Salomon M. Stemmer
Publikováno v:
Cancer Research. 81:CT178-CT178
Background: Poly-ADP-ribose polymerase (PARP) inhibition plus PD-(L)1 blockade has shown encouraging antitumor activity in patients (pts) with recurrent ovarian or breast cancer with BRCAm and in pts with recurrent ovarian cancer regardless of BRCAm
Autor:
Jung Ho Sohn, Wichit Arpornwirat, O Ocak Arikan, Y-C Chang, Roberta Valenti, Patricia Bastick, S-A Im, Hong-Ling Xue, KS Lee, Kadri Altundag, Alper Sevinc, TH Le, Hikmat Abdel-Razeq, Aycin Canatar, Y-H Im, Jae Ho Jeong, Ruchan Uslu, Rajnish Nagarkar, H-S Park, S-B Kim
Publikováno v:
Cancer Research. 76:P4-13
Background BOLERO-2 phase III trial established the efficacy of everolimus (EVE) plus exemestane (EXE) for the treatment of postmenopausal patients with hormone receptor (HR)-positive, HER2-negative, advanced breast cancer (aBC). However, in this stu
Autor:
Weizhe Xue, Hua-Jun Chen, Renhua Guo, Hao Liu, Qing Zhou, Bin Gan, Yi-Long Wu, Lu Zhang, Lin Wu, Shuyin Chen, Han-Zhang Han, Jin-Ji Yang, Xinru Mao, Yun Fan, Hepeng Shi, Xuan Lin, Peilong Zhang, Jun Zhao
Publikováno v:
Cancer Research. 80:CT127-CT127
Introduction: Cellular mesenchymal-epithelial transition (cMET) dysregulation has been described in non-small-cell lung cancer (NSCLC) and implicated as a negative prognostic factor. It can occur as amplification, overexpression or mutations leading
Autor:
Christopher Flynn, Jill M. Kolesar, Kari B. Wisinski, Moniba Nazeef, Jens C. Eickhoff, Mark E. Burkard, Amye J. Tevaarwerk, Jennifer Heideman, Glenn Liu
Publikováno v:
Cancer Research. 75:P5-19
Background : AKT mediates signaling in the human epidermal growth factor receptor-2 (HER2) pathway. HER2 inhibition can result in feedback regulation of signaling, leading to high AKT activity. Preclinical studies demonstrate activity of combined HER
Autor:
Niven R. Narain, Vladimir Tolstikov, Emily Y. Chen, Pao-Hwa Lin, Rangaprasad Sarangarajan, Jen-Tsan Chi, Michael A. Kiebish, Stephen J. Freedland
Publikováno v:
Cancer Research. 79:4900-4900
Background: Prostate cancer (PrCa) is one of the most common cancers among men and managed through surgery, hormonal therapy, chemotherapy, radiation, and cryotherapy. Depending on the stage of PrCa, androgen deprivation therapy (ADT) is commonly uti
Autor:
Jon Hersch, Anna M. Varghese, Fabio Benedetti, Al B. Benson, Kensuke Hamada, Dana Backlund Cardin, Howard S. Hochster, Leonard B. Saltz, Jordan Berlin, Robert Winkler
Publikováno v:
Cancer Research. 78:CT062-CT062
Background: FTD/TPI combines a thymidine-based nucleoside analog, FTD, and a thymidine phosphorylase inhibitor, TPI, and is approved for previously treated patients with metastatic colorectal cancer (mCRC). Preclinical results with FTD/TPI indicated
Publikováno v:
Cancer Research. 74:4861-4861
Caffeine's mechanism of action on immune cells has been an issue of debate for some time. Previous studies suggest caffeine inhibits cyclic AMP (cAMP)-phosphodiesterase, resulting in increased cAMP levels, increased protein kinase A (PKA) activation,
Autor:
Esa Alhoniemi, Dana T. Aftab, Jussi M. Halleen, Mari I. Suominen, Rami Käkönen, Katja M. Fagerlund, Jukka P. Rissanen, Douglas O. Clary
Publikováno v:
Cancer Research. 74:734-734
Cabozantinib is an inhibitor of tyrosine kinases including MET, VEGFR2, and RET, and has shown clinical activity in patients with castration-resistant prostate cancer and other solid tumors with bone metastases. Multiple myeloma (MM) is the second mo